AU2014293665B2 - Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent - Google Patents

Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent Download PDF

Info

Publication number
AU2014293665B2
AU2014293665B2 AU2014293665A AU2014293665A AU2014293665B2 AU 2014293665 B2 AU2014293665 B2 AU 2014293665B2 AU 2014293665 A AU2014293665 A AU 2014293665A AU 2014293665 A AU2014293665 A AU 2014293665A AU 2014293665 B2 AU2014293665 B2 AU 2014293665B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
injection
pathology
condition
triamcinolone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014293665A
Other languages
English (en)
Other versions
AU2014293665A1 (en
Inventor
Bernard Covalesky
Richard Dilzer
John Scott Karolchyk
Jeffery T. LIEGNER
Kallan Peters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eye Care Northwest Pa
Novel Drug Solutions LLC
Original Assignee
Eye Care Northwest Pa
Novel Drug Solutions LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50640013&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2014293665(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eye Care Northwest Pa, Novel Drug Solutions LLC filed Critical Eye Care Northwest Pa
Publication of AU2014293665A1 publication Critical patent/AU2014293665A1/en
Application granted granted Critical
Publication of AU2014293665B2 publication Critical patent/AU2014293665B2/en
Assigned to HARROW HEALTH, INC. reassignment HARROW HEALTH, INC. Request to Amend Deed and Register Assignors: IMPRIMIS PHARMACEUTICALS, INC.
Assigned to EYE CARE NORTHWEST, PA, NOVEL DRUG SOLUTIONS LLC reassignment EYE CARE NORTHWEST, PA Request for Assignment Assignors: HARROW HEALTH, INC.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU2014293665A 2013-07-22 2014-03-27 Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent Active AU2014293665B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361958170P 2013-07-22 2013-07-22
US61/958,170 2013-07-22
PCT/US2014/032026 WO2015012899A1 (en) 2013-07-22 2014-03-27 Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent

Publications (2)

Publication Number Publication Date
AU2014293665A1 AU2014293665A1 (en) 2016-02-11
AU2014293665B2 true AU2014293665B2 (en) 2017-06-01

Family

ID=50640013

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014293665A Active AU2014293665B2 (en) 2013-07-22 2014-03-27 Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent

Country Status (10)

Country Link
US (1) US20150024996A1 (enExample)
EP (1) EP3024475B8 (enExample)
JP (5) JP2016525544A (enExample)
KR (1) KR20160033213A (enExample)
AU (1) AU2014293665B2 (enExample)
BR (1) BR112016001544A8 (enExample)
CA (1) CA2919081C (enExample)
IL (1) IL243750A0 (enExample)
MX (1) MX383077B (enExample)
WO (1) WO2015012899A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
KR20160033213A (ko) * 2013-07-22 2016-03-25 임프리미스 파마슈티컬스 인코포레이티드 항균제 및 항염증제를 포함하는 안구내 투여를 위한 약학적 조성물
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
JP6682898B2 (ja) * 2016-02-17 2020-04-15 富士通株式会社 基地局、無線通信システムおよび基地局の処理方法
KR20190109604A (ko) * 2016-05-06 2019-09-25 해로우 헬스 인코포레이티드 약학적 안과용 조성물 및 그의 제조 방법
DK3541442T3 (da) 2016-11-16 2022-03-14 Persica Pharmaceuticals Ltd Antibiotiske formuleringer mod lændesmerter
US11071724B2 (en) 2019-05-17 2021-07-27 Ocular Science, Inc. Compositions and methods for treating presbyopia
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US11484538B2 (en) 2020-08-26 2022-11-01 Somerset Therapeutics, Llc Bromfenac, prednisolone, and moxifloxacin compositions and methods
US11523987B2 (en) 2020-08-26 2022-12-13 Somerset Therapeutics, Llc Trimcinolone and moxifloxacin methods
US11382910B2 (en) 2020-08-26 2022-07-12 Somerset Therapeutics, Llc. Loteprednol and moxifloxacin compositions and methods
EP4260844A1 (en) 2022-04-11 2023-10-18 Liegner, Jeffery T. Ophthalmological compositions comprising poloxamer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20100239637A1 (en) * 2008-12-11 2010-09-23 Massachusetts Institute Of Technology Contact lens drug delivery device
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1192368A (ja) * 1997-07-23 1999-04-06 Ono Pharmaceut Co Ltd ベンゾピラン誘導体を主成分とする水性液剤
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
JP2003176228A (ja) * 2001-12-11 2003-06-24 Rohto Pharmaceut Co Ltd 液 剤
DE602006006308D1 (de) * 2005-05-10 2009-05-28 Alcon Inc Suspensionsformulierungen mit einem aktiven wirkstoff, einem poloxamer- oder meroxapol-tensid und einem glycol und ihre verwendung zur herstellung eines medikaments zur behandlung von augenkrankheiten
US20080262415A1 (en) * 2005-07-18 2008-10-23 Peyman Gholam A Enhanced wound healing
JP2013508381A (ja) * 2009-10-21 2013-03-07 オトノミ―，インク． ポロクサマーを包含する製剤のゲル化温度の調節
US20140127269A1 (en) * 2012-02-13 2014-05-08 The Schepens Eye Research Institute, Inc. Anti-Inflammatory Peptide Derived From Thrombospondin-1 and Uses Thereof
KR20160033213A (ko) * 2013-07-22 2016-03-25 임프리미스 파마슈티컬스 인코포레이티드 항균제 및 항염증제를 포함하는 안구내 투여를 위한 약학적 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049552A1 (en) * 2003-04-14 2007-03-01 Babu Manoj M Fluoroquinolone formulations and methods of making and using the same
US20100239637A1 (en) * 2008-12-11 2010-09-23 Massachusetts Institute Of Technology Contact lens drug delivery device
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Angelucci, D (2006) Best Paper Of Session Intracameral injection studied to replace post-op eyedrops. [Retrieved from internet on 1 September 2016] <URL: http://www.eyeworld.org/article.php?sid=2918 > *
Ermis, SS et al (2005) Tohoku J. Exp. Med. 205: 223-229 *
Liegner, J et al (2012) [Retrieved from internet 1 September 2016] [Online Video] <URL: http://ascrs2012.conferencefilms.com/atables.wcs?entryid=100047> *
Lipner, M (2012) Perioperative pharmacology Bucking the drop trend. [Retrieved from internet on 1 September 2016] <URL: http://eyeworld.org/printarticle.php?id=6353 > *
Mangan, RB et al (2013) Primary Care Optometry News 18: 16 # *
Paganelli, F et al (2009) Investigative Ophthalmology & Visual Science 50: 3041-3047 *
Sakalar, YB et al (2011) Journal of Ocular Pharmacology and Therapeutics 27: 593-598 *
Wiskur, BJ et al (2008) Investigative Ophthalmology & Visual Science 49: 1480-1487 *

Also Published As

Publication number Publication date
EP3024475A1 (en) 2016-06-01
JP2021121608A (ja) 2021-08-26
AU2014293665A1 (en) 2016-02-11
NZ716208A (en) 2020-12-18
HK1223824A1 (zh) 2017-08-11
JP2022185059A (ja) 2022-12-13
IL243750A0 (en) 2016-04-21
JP2019167376A (ja) 2019-10-03
MX2016000964A (es) 2016-08-03
MX383077B (es) 2025-03-13
JP7362870B2 (ja) 2023-10-17
CA2919081C (en) 2021-11-16
JP2016525544A (ja) 2016-08-25
BR112016001544A2 (pt) 2017-07-25
CA2919081A1 (en) 2015-01-29
EP3024475B1 (en) 2020-09-30
WO2015012899A1 (en) 2015-01-29
JP2024001149A (ja) 2024-01-09
BR112016001544A8 (pt) 2021-08-03
KR20160033213A (ko) 2016-03-25
EP3024475B8 (en) 2020-11-18
JP7232128B2 (ja) 2023-03-02
US20150024996A1 (en) 2015-01-22

Similar Documents

Publication Publication Date Title
JP7362870B2 (ja) 抗菌剤及び抗炎症剤を含む眼内投与のための医薬組成物
US11684570B2 (en) Pharmaceutical ophthalmic compositions
US11510916B2 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160184323A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20150129457A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160101118A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20160243031A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20160175323A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
AU2017260327B2 (en) Pharmaceutical Ophthalmic compositions and methods for fabricating thereof
US20190105320A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US20190111045A1 (en) Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US9814673B2 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
WO2016024956A1 (en) Intraocular lens comprising fluoroquinolone and a corticosteroid and methods for fabricating thereof
US20160045432A1 (en) Intraocular lens comprising pharmaceutical compositions and methods for fabricating thereof
HK40105104A (en) Ophthalmological compositions comprising poloxamer
EP4260844A1 (en) Ophthalmological compositions comprising poloxamer
HK1223824B (en) Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent
WO2020117497A1 (en) Pharmaceutical compositions for intraocular administration and methods for fabricating thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: HARROW HEALTH, INC.

Free format text: FORMER NAME(S): IMPRIMIS PHARMACEUTICALS, INC.

PC Assignment registered

Owner name: EYE CARE NORTHWEST, PA

Free format text: FORMER OWNER(S): HARROW HEALTH, INC.

Owner name: NOVEL DRUG SOLUTIONS LLC

Free format text: FORMER OWNER(S): HARROW HEALTH, INC.